Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study

European Journal of Cancer

Volumn 45, Issue 9, 2009, Pages 1603-1615

  Ludwig, Heinz ^a   Aapro, Matti ^b   Bokemeyer, Carsten ^c   MacDonald, Karen ^d   Soubeyran, Pierre ^e   Turner, Matthew ^f   Albrecht, Tara ^d,g   Abraham, Ivo ^d,h  

^a Wilhelminenspital   (Austria)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Matrix45 ^*  (United States)

^e INSTITUT BERGONIÉ   (France)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g UNIVERSITY OF VIRGINIA   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

Author keywords

Anaemia; Cancer; Erythropoietin; Europe; Haemoglobin; Outcomes; Response; Treatment patterns

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; EUROPE; FEMALE; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GUIDELINE ADHERENCE; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66149150959     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.02.003     Document Type: Article

References (22)

1. Ludwig H., and Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 25 Suppl. 7 (1998) 35-38
2. Ludwig H., Van Belle S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004) 2293-2306
3. Blohmer J.U., Dunst J., Harrison L., et al. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 68 Suppl. 1 (2005) 12-21
4. Caro J.J., Salas M., Ward A., and Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91 (2001) 2214-2221
5. Nissenson A.R., Goodnough L.T., and Dubois R.W. Anemia: not just an innocent bystander?. Arch Intern Med 163 (2003) 1400-1404
6. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25 (1998) 43-46
7. Giardiola E., Morschhauser F., Zambroski J.J., et al. Prise en charge de l'anémie chez les patients présentant une pathologie maligne: résultats de l'étude F-ACT (French Anaemia Cancer Treatment) [Managment of anaemia with cancer: results of the F-ACT study (French Anaemia Cancer Treatment)]. Bull Cancer 94 (2007) 907-914
8. Rizzo J.D., Lichtin A.E., Woolf S.H., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20 (2002) 4083-4107
9. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical practice guideline update. J Clin Oncol 26 (2008) 132-149
10. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40 (2004) 2201-2216
11. Bokemeyer C., Aapro M.S., Courdi A., et al. European Organisation for Research and Treatment of Cancer (EORTC) taskforce for the elderly, EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43 (2007) 258-270
12. Aapro M.S., and Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13 (2008) 33-36
13. Aapro M., Abraham I., Bokemeyer C., et al. The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Support Care Cancer 16 (2008) 193-200
14. Aapro M., Erps J., MacDonald K., et al. Managing cancer-related anemia in congruence with the EORTC guidelines is an independent predictor of hemoglobin outcome: initial evidence from the RESPOND study. Eur J Cancer 45 (2009) 8-11
15. Littlewood T.J., Bajetta E., Nortier J.W.R., et al. Effects of epoetin alfa on haematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
16. Osterborg A., Brandberg Y., Molostova V., et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20 (2002) 2486-2494
17. Glaspy J., Bukowski R., Steinberg D., et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15 (1997) 1218-1234
18. Demetri G.D., Kris M., Wade J., et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16 (1998) 3412-3425
19. Gabrilove J., Cleeland C.S., Livingston R.B., et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19 (2001) 2875-2882
20. Fallowfield L., Gagnon D., Zagari M., et al. Multivariate regression analyses of data from a randomised, double-blind, placebocontrolled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Brit J Cancer 87 (2002) 1341-1353
21. Anonymous. Erythropoietin analogues: an unnecessary class of drugs. Lancet Oncol 2008;9:81.
22. Aapro M.S., Birgegard G., Bokemeyer C., et al. Erythropoietins should be used according to guidelines. Lancet Oncol 9 (2008) 412-413